The female sexual function index: reliability and validity in Spanish postmenopausal women

Pérez-Herrezuelo, I.; Hita‐Contreras, Fidel; Martínez‐Amat, Antonio; Aibar-Almazán, Agustín; Cruz‐Díaz, David; Wangensteen, Rosemary; Achalandabaso‐Ochoa, Alexander; Díaz-Mohedo, Esther

doi:10.1097/gme.0000000000001305

Cited by 14 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study by Pérez-Herrezuelo validates the Spanish version of FSFI and also reported decreased sexual function among postmenopausal women [45]. Among the reasons cited for low sexual desire in our study by the women participants, vaginal dryness (35.7%) was the most common.…”

Section: Discussionsupporting

confidence: 55%

Decreased Sexual Desire among Middle-Aged and Old Women in China and Factors Influencing It: A Questionnaire-Based Study

Zhu

Yang

Fan³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This survey was designed and conducted with an aim to present data on sexual desire and activity in Chinese women. Methods. Between October 2013 and December 2013, we surveyed 3000 women (aged 40–65 years) at Beijing No. 2 Hospital and the Yuetan Community Health Service Center using a questionnaire. The primary outcomes included determination of sexual desire in the past 4 weeks, reasons for stopping sexual activity, and postmenopausal syndrome. The secondary outcome was determination of factors for low sexual desire. Results. A total of 2400 women (mean age 54.33 ± 6.25 years; mean menopausal age 50.11 ± 3.31 years) returned the questionnaire, with 58% of women reporting lowered sexual desire and 39.3% reporting stoppage of sexual activity. Compared with the postmenopausal group, the incidence of anxiety, depressive, somatic, and vasomotor symptoms was higher in the perimenopausal group. Muscle and joint pain (45.8%) and vaginal pruritus (21.5%) were the most commonly reported menopausal and vulvovaginal symptoms, respectively. The odds of decrease in sexual desire were significantly higher with older age, menopause, presence of gynecological disease, menopausal depression symptoms, menopausal vasomotor symptoms, and vulvovaginal atrophy; only cesarean delivery (odds ratio = 0.887, P = 0.018 ) was associated with lesser reduction in sexual desire compared with the aforementioned factors. Conclusion. This survey showed that a high proportion of Chinese middle-aged and old women have lowered sexual desire and activity. Lack of sexual desire is associated with multiple factors and affects the quality of life of women.

show abstract

Section: Discussionsupporting

confidence: 55%

Decreased Sexual Desire among Middle-Aged and Old Women in China and Factors Influencing It: A Questionnaire-Based Study

Zhu

Yang

Fan³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In our study 70.88% of participants presented sexual dysfunction, which is a lower frequency than reported in previous studies employing the FSFI and carried out among postmenopausal women of similar mean age [32,36]. Such difference may be attributable to the fact that those studies employed the traditional FSFI cut-off point described in a study that dealt with several samples of women of a wide range of ages (18-74 years) [37], while we used a cut-off point specifically indicated for an older population [20].…”

Section: Discussionmentioning

confidence: 90%

“…Domain scores range from 0 (or 1) to 5, and the sum of the scores of all domains generates a total which indicates better sexual function the higher the score. In this study we used the validated version of the Spanish FSFI, with a score <24.95 representing a high risk of sexual dysfunction [20].…”

Section: Female Sexual Functionmentioning

confidence: 99%

Female Sexual Function and Its Association with the Severity of Menopause-Related Symptoms

Pérez-Herrezuelo

Aibar-Almazán

Martínez‐Amat

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

The aim of this study was to examine female sexual functioning and its association with the impact of the symptoms of menopause among Spanish postmenopausal women. A total of 182 postmenopausal women (65.59 ± 7.93 years) participated in this cross-sectional study. The female sexual function index (FSFI) and the menopause rating scale (MRS) were used to analyze sexual function and severity of menopausal symptoms, respectively. Age, education, area of residence, occupation, and depression (Hospital Anxiety and Depression Scale) were considered as possible confounders. The results of a linear multivariate regression analysis showed that the severity of urogenital menopause-related symptoms was associated with lower values in the FSFI total score and the lubrication, satisfaction, arousal, and orgasm domains. These last three subscales were also linked to severe psychological impact, while the MRS total score was only related to the desire domain. Regarding confounders, being younger, working, and residing in a rural area were all linked to better sexual function. All effect sizes were large (adjusted R2 > 0.35). In conclusion, after controlling for possible confounders, postmenopausal women who experience a severe impact of menopausal symptoms endure poorer sexual function, particularly when said symptoms are urogenital or psychological in nature.

show abstract

“…FSFI has been validated for women with cancer [14]. The Spanish FSFI is a valid and reliable instrument for assessing and discriminating FSD among Spanish postmenopausal women [15].…”

Section: Methodsmentioning

confidence: 99%

Sexual Dysfunction in Postmenopausal Women with Breast Cancer on Adjuvant Aromatase Inhibitor Therapy

López

Hinojo²,

Sánchez‐Prieto

et al. 2020

Breast Care

View full text Add to dashboard Cite

Introduction: The aim of this study was to investigate whether postmenopausal women with breast cancer (BC) on adjuvant aromatase inhibitor (AI) therapy have a higher prevalence of female sexual dysfunction (FSD). Second, the aim was to determine the quality of life (QoL) and level of anxiety depending on whether or not they are AI users. Methods: A prospective cross-sectional study involving 168 patients was performed. Three questionnaires were carried out: sexual functioning was evaluated with the Female Sexual Function Index (FSFI), while the EORTC QLQ-BR23 measures to study QoL in patients with BC and the State-Trait Anxiety Inventory (STAI) questionnaire (trait and status) were used to assess anxiety status in patients under treatment with AIs or not. Results: 47.6% (80/168) of the postmenopausal BC survivors were not sexually active (mean time after surgery: 48.6 months) despite a relatively low mean age (56.43 years). Postmenopausal AI-treated women had significantly worse sexual function as measured by the FSFI (23.40 ± 5.26 vs. 30.16 ± 2.24; p = 0.000). There were significant differences between both groups in all domains, except orgasm. The QoL score was 37.67 ± 7.38 in AI users versus 39.00 ± 1.44 among nonusers (p = 0.053). Patients under endocrine treatment also presented STAI scores significantly higher (25.83 ± 4.99 vs. 19.00 ± 7.12; p = 0.000). Trait anxiety was high in both groups, but this was not statistically significant. Conclusions: We observed a high prevalence of sexual inactivity among BC survivors regardless of AI use. Patients with AI use presented significantly higher prevalence of FSD, worse QoL, and greater anxiety.

show abstract

The female sexual function index: reliability and validity in Spanish postmenopausal women

Cited by 14 publications

References 38 publications

Decreased Sexual Desire among Middle-Aged and Old Women in China and Factors Influencing It: A Questionnaire-Based Study

Decreased Sexual Desire among Middle-Aged and Old Women in China and Factors Influencing It: A Questionnaire-Based Study

Female Sexual Function and Its Association with the Severity of Menopause-Related Symptoms

Sexual Dysfunction in Postmenopausal Women with Breast Cancer on Adjuvant Aromatase Inhibitor Therapy

Contact Info

Product

Resources

About